Sirona Biochem Corp.
SRBCF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.24 | -0.47 | -0.39 |
| FCF Yield | -4.09% | -3.77% | -2.45% | -1.29% |
| EV / EBITDA | -25.36 | -49.94 | -37.22 | -36.16 |
| Quality | ||||
| ROIC | 2,434.94% | 161.10% | 232.25% | 299.69% |
| Gross Margin | 100.00% | 77.84% | -52.83% | 108.06% |
| Cash Conversion Ratio | 0.62 | 1.64 | 0.74 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -56.47% | -57.68% |
| Free Cash Flow Growth | 19.60% | -26.55% | -124.47% | 55.14% |
| Safety | ||||
| Net Debt / EBITDA | -4.96 | -6.45 | -3.41 | -2.85 |
| Interest Coverage | -3.00 | 0.00 | -10.64 | -4.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 27,168.75 | -26,982.76 | -36,535.62 | -40,807.60 |